Roche Says It Will Launch Mircera

Law360, New York (February 7, 2007, 12:00 AM EST) -- Roche Holding AG said Wednesday that it would begin marketing its anemia drug Mircera in the United States as soon as it receives Food and Drug Administration approval, despite an ongoing patent infringement dispute with rival Amgen Inc.

The FDA is expected to approve Mircera sometime in the middle of the year. If Roche then begins selling the drug, it could be subject to triple damages if it loses the suit against Amgen.

Nonetheless, Roche said it was confident of winning the case.

“Mircera…differs from existing...
To view the full article, register now.